199 related articles for article (PubMed ID: 29891487)
1. Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.
Leconet W; Liu H; Guo M; Le Lamer-Déchamps S; Molinier C; Kim S; Vrlinic T; Oster M; Liu F; Navarro V; Batra JS; Noriega AL; Grizot S; Bander NH
Mol Cancer Ther; 2018 Sep; 17(9):1927-1940. PubMed ID: 29891487
[TBL] [Abstract][Full Text] [Related]
2. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
[TBL] [Abstract][Full Text] [Related]
3. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
Chiu D; Tavaré R; Haber L; Aina OH; Vazzana K; Ram P; Danton M; Finney J; Jalal S; Krueger P; Giurleo JT; Ma D; Smith E; Thurston G; Kirshner JR; Crawford A
Cancer Immunol Res; 2020 May; 8(5):596-608. PubMed ID: 32184296
[TBL] [Abstract][Full Text] [Related]
4. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
[TBL] [Abstract][Full Text] [Related]
5. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
6. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
[TBL] [Abstract][Full Text] [Related]
7. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
8. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
[TBL] [Abstract][Full Text] [Related]
9. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
10. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
12. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
13. PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
Owiti AO; Pal D; Mitra A
AAPS PharmSciTech; 2018 Nov; 19(8):3534-3549. PubMed ID: 30151731
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
15. PSMA-targeted bispecific Fab conjugates that engage T cells.
Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
17. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
18. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
19. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
20. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
